Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

References

• Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–444. doi:10.2337/diacare.16.2.434
   PubMed Web of Science ®Google Scholar
• Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med. 2017;34:887–901. doi:10.1111/dme.13324
   PubMed Web of Science ®Google Scholar
• Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med. 2004;351:1344–1346. doi:10.1056/NEJMe048211
   PubMed Web of Science ®Google Scholar
• van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–1352.
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24. doi:10.1016/S0167-0115(99)00089-0
   PubMed Web of Science ®Google Scholar
• Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120–2131. doi:10.2337/db13-1029
   PubMed Web of Science ®Google Scholar
• Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009;200:53–61. doi:10.1677/JOE-08-0424
   PubMed Web of Science ®Google Scholar
• Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992–1019. doi:10.1210/er.2014-1035
   PubMed Web of Science ®Google Scholar
• Muskiet MH, Smits MM, Morsink LM, et al. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10:88–103. doi:10.1038/nrneph.2013.272
   PubMed Web of Science ®Google Scholar
• Crowley MJ, Williams JW Jr., Kosinski AS, et al. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care. 2017;40:1787–1789. doi:10.2337/dc17-1528
   PubMed Web of Science ®Google Scholar
• Kårhus ML, Brønden A, Sonne DP, et al. Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review. Diabetes Obes Metab. 2017;19:1214–1222. doi:10.1111/dom.12946
   PubMedGoogle Scholar
• Bahne E, Hansen M, Brønden A, et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab. 2016;18:955–961. doi:10.1111/dom.12697
   PubMedGoogle Scholar
• Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–335. doi:10.1046/j.1463-1326.2002.00219.x
   PubMed Web of Science ®Google Scholar
• Aoki K, Miyazaki T, Nagakura J, et al. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide levels in healthy men. Endocr J. 2010;57:673–677. doi:10.1507/endocrj.K10E-064
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58:69–73. doi:10.1507/endocrj.K10E-382
   PubMed Web of Science ®Google Scholar
• Groop P-H, Cooper ME, Perkovic V, et al. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: rationale and design of the MARLINA-T2D™ trial. Diab Vasc Dis Res. 2015;12:455–462. doi:10.1177/1479164115579002
   PubMedGoogle Scholar
• Mori H, Okada Y, Arao T, et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Invest. 2014;5:313–319. doi:10.1111/jdi.12142
   PubMed Web of Science ®Google Scholar
• Goldshtein I, Karasik A, Melzer-Cohen C, et al. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study. J Diabetes Complications. 2016;30:1354–1359. doi:10.1016/j.jdiacomp.2016.05.012
   PubMedGoogle Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• Trevisan R, Dodesini AR. The hyperfiltering kidney in diabetes. Nephron. 2017;136:277–280. doi:10.1159/000448183
   PubMedGoogle Scholar
• White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kahn SE, Johansen OE, et al. CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA Randomized Clinical Trial. JAMA. 2019;322:1155–1166. doi:10.1001/jama.2019.13772
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Cornel JH, Bakris GL, Stevens SR, et al. TECOS Study Group. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39:2304–2310. doi:10.2337/dc16-1415
   PubMed Web of Science ®Google Scholar
• Osonoi T, Saito M, Hariya N, et al. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin. Peptides. 2016;86:118–125. doi:10.1016/j.peptides.2016.10.011
   PubMedGoogle Scholar
• Murayama H, Imai K, Odawara M. Factors influencing the prescribing preferences of physicians for drug-naive patients with type 2 diabetes mellitus in the real-world setting in Japan: insight from a web survey. Diabetes Ther. 2018;9:1185–1199. doi:10.1007/s13300-018-0431-3
   PubMed Web of Science ®Google Scholar
• Kitada M, Kanasaki K, Koya D. Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes. 2014;5:342–356. doi:10.4239/wjd.v5.i3.342
   PubMedGoogle Scholar
• Vejakama P, Ingsathit A, McKay GJ, et al. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. BMC Nephrol. 2017;18:342. doi:10.1186/s12882-017-0753-9.
   PubMed Web of Science ®Google Scholar
• Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012;82:589–597. doi:10.1038/ki.2012.189
   PubMed Web of Science ®Google Scholar